We are live on ! Find out more

53 hedge funds and large institutions have $64.1M invested in Exagen in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 5

229% more call options, than puts

Call options by funds: $56K | Put options by funds: $17K

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

186% more capital invested

Capital invested by funds: $22.4M → $64.1M (+$41.7M)

39% more funds holding

Funds holding: 3853 (+15)

7.25% more ownership

Funds ownership: 34.84%42.09% (+7.2%)

Holders
53
Holders Change
+15
Holders Change %
+39.47%
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
17
Reduced
5
Closed
7
Calls
$56K
Puts
$17K
Net Calls
+$39K
Net Calls Change
+$87K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
51
Fidelity Investments
Massachusetts
$2.49K +$2.17K +357 New
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$237 +$30 +5 +17%
JP Morgan Chase
53
JP Morgan Chase
New York
$35
Hudson Bay Capital Management
54
Hudson Bay Capital Management
Connecticut
-$598K -166,705 Closed
Marshall Wace
55
Marshall Wace
United Kingdom
-$383K -106,559 Closed
SCM
56
Stonepine Capital Management
Oregon
-$344K -95,747 Closed
Prudential Financial
57
Prudential Financial
New Jersey
-$58.2K -16,200 Closed
GCP
58
GSA Capital Partners
United Kingdom
-$44K -12,287 Closed
Citadel Advisors
59
Citadel Advisors
Florida
-$15.4K -4,284 Closed
TRCT
60
Tower Research Capital (TRC)
New York
-$223 -62 Closed

XGN Hedge Fund Activity: Q2 2025 in Review

53 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q2 2025, worth a combined $64.1M — up 186% from $22.4M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new XGN positions and 7 closed out — a net gain of 15 holders — while 17 added to existing stakes and 5 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $4.37M. The largest seller was Perkins Capital Management, cutting an estimated $1.16M.

  • 53 institutional investors held Exagen (XGN) as of Q2 2025, up from 38 in Q1 2025.
  • Funds reported $64.1M of Exagen stock for Q2 2025, up 186% quarter-over-quarter.
  • 22 funds opened new Exagen positions in Q2 2025 and 7 closed out, a net change of +15 holders.
  • The largest Exagen buyer in Q2 2025 was Balyasny Asset Management, an estimated $4.37M added.
  • The largest Exagen seller in Q2 2025 was Perkins Capital Management, an estimated $1.16M sold.

Based on aggregated 13F filings for Q2 2025.